bioAffinity Technologies, Inc. Accounts Payable
bioAffinity Technologies, Inc. (BIAF) had Accounts Payable of $969.85 thousand as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-08-07
- 2026-06-30: Accounts Payable, Current $969.85K.
- 2026-03-31: Accounts Payable, Current $836.21K.
- 2025-12-31: Accounts Payable, Current $761.90K.
- 2025-09-30: Accounts Payable, Current $940.76K.
| Period end | Accounts Payable, Current |
|---|---|
| 2026-06-30 | $969.85K 10-Q · filed 2026-08-07 |
| 2026-03-31 | $836.21K 10-Q · filed 2026-05-11 |
| 2025-12-31 | $761.90K 10-Q · filed 2026-08-07 |
| 2025-09-30 | $940.76K 10-Q · filed 2025-11-14 |
| 2025-06-30 | $1.17M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $1.38M 10-Q · filed 2025-05-15 |
| 2024-12-31 | $987.31K 10-K · filed 2026-03-16 |
| 2024-09-30 | $782.94K 10-Q · filed 2024-11-14 |
| 2024-06-30 | $848.10K 10-Q · filed 2024-08-14 |
| 2024-03-31 | $383.99K 10-Q · filed 2024-05-15 |
| 2023-12-31 | $604.79K 10-K · filed 2025-03-31 |
| 2023-09-30 | $827.41K 10-Q · filed 2023-11-14 |
| 2023-06-30 | $174.40K 10-Q · filed 2023-08-14 |
| 2023-03-31 | $146.54K 10-Q · filed 2023-05-15 |
| 2022-12-31 | $345.04K 10-K · filed 2024-04-01 |
| 2022-09-30 | $149.87K 10-Q · filed 2022-11-14 |
| 2021-12-31 | $230.41K 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |